Literature DB >> 17470843

Sirolimus treatment for pulmonary lymphangioleiomyomatosis.

Camille Taillé, Marie-Pierre Debray, Bruno Crestani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17470843     DOI： 10.7326/0003-4819-146-9-200705010-00022

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  11 in total

Review 1.  Advances in sarcoma genomics and new therapeutic targets.

Authors:  Barry S Taylor; Jordi Barretina; Robert G Maki; Cristina R Antonescu; Samuel Singer; Marc Ladanyi
Journal:  Nat Rev Cancer       Date:  2011-07-14       Impact factor: 60.716

2.  Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.

Authors:  Angelo M Taveira-DaSilva; Olanda Hathaway; Mario Stylianou; Joel Moss
Journal:  Ann Intern Med       Date:  2011-06-21       Impact factor: 25.391

Review 3.  Optimizing treatments for lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-DaSilva; Joel Moss
Journal:  Expert Rev Respir Med       Date:  2012-06       Impact factor: 3.772

4.  Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma.

Authors:  Darcy A Krueger; Marguerite M Care; Karen Agricola; Cindy Tudor; Maxwell Mays; David Neal Franz
Journal:  Neurology       Date:  2013-01-16       Impact factor: 9.910

5.  Multimodality therapy for metastatic sarcomas confined to the lung.

Authors:  Russell P Gollard; J Francis Turner
Journal:  Oncol Lett       Date:  2012-07-24       Impact factor: 2.967

Review 6.  Lymphangioleiomyomatosis and tuberous sclerosis complex.

Authors:  Dimitrios Chorianopoulos; Grigoris Stratakos
Journal:  Lung       Date:  2008-04-12       Impact factor: 2.584

7.  Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.

Authors:  Andrew J Wagner; Izabela Malinowska-Kolodziej; Jeffrey A Morgan; Wei Qin; Christopher D M Fletcher; Natalie Vena; Azra H Ligon; Cristina R Antonescu; Nikhil H Ramaiya; George D Demetri; David J Kwiatkowski; Robert G Maki
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544

Review 8.  Current management of tuberous sclerosis complex.

Authors:  Darcy A Krueger; David N Franz
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

9.  Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?

Authors:  Claus Neurohr; Anna L Hoffmann; Patrick Huppmann; Vivian A Herrera; Franziska Ihle; Stefan Leuschner; Werner von Wulffen; Tobias Meis; Carlos Baezner; Hanno Leuchte; Rainer Baumgartner; Gregor Zimmermann; Juergen Behr
Journal:  Respir Res       Date:  2011-05-21

10.  mTOR Inhibitors in Tuberous Sclerosis Complex.

Authors:  Paolo Curatolo; Romina Moavero
Journal:  Curr Neuropharmacol       Date:  2012-12       Impact factor: 7.363
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.